Eli Lilly’s lepodisiran cuts lipoprotein(a) by 93.9% in Phase II trial
The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.
Fierce Biotech4h
Lilly links lepodisiran to durably lower lipoprotein in phase 2, providing edge over Amgen and Novartis
Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...
Comisión europea sugiere no aprobar comercialización de fármaco de Lilly contra Alzheimer
Por THE ASSOCIATED PRESSUna comisión reguladora europea rechazó el tratamiento de Eli Lilly contra la enfermedad de Alzheimer ...
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
No serious adverse events related to the drug were reported. "What we have is a drug that can lower lipoprotein(a) with very ...
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Eli Lilly and Company (LLY): Among Billionaire Ken Fisher’s Top Growth Stock Picks
We recently published a list of Billionaire Ken Fisher’s Top 13 Growth Stock Picks. In this article, we are going to take a ...
Explore more
5 Reasons It's Not Too Late to Buy Eli Lilly Stock
Eli Lilly (LLY 1.80%) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...
Eli Lilly's Alzheimer's drug rejected in Europe
The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...
EU regulator rejects Eli Lilly's Alzheimer's drug
The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's small impact on ...